Semaglutide vs Retatrutide: Dual Agonist vs Triple Agonist
Semaglutide changed weight management. Retatrutide may change it again — adding a third receptor target (glucagon) for even greater metabolic impact. Here's the evidence-based comparison.
Semaglutide (Ozempic/Wegovy) redefined weight management by proving that pharmacological intervention could achieve weight loss comparable to bariatric surgery. Tirzepatide (Mounjaro/Zepbound) raised the bar by adding GIP receptor activation alongside GLP-1. Now Retatrutide enters as a triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously.
For women dealing with menopause-related metabolic changes, PCOS insulin resistance, or significant weight management needs, understanding the differences between these next-generation incretin therapies is critical for making informed treatment decisions.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP + Glucagon (triple) |
| Weight loss (trials) | ~15-17% (STEP trials) | ~24% at highest dose (Phase 2) |
| FDA status | Approved (Wegovy/Ozempic) | Investigational (Phase 3 ongoing) |
| Mechanism advantage | Well-understood, extensive safety data | Glucagon receptor adds energy expenditure + liver fat reduction |
| GI side effects | Nausea common (esp. titration) | Nausea reported, may be higher at top doses |
| Cardiovascular data | Proven CV benefit (SELECT trial) | No CV outcome data yet |
| PCOS relevance | Improves insulin sensitivity, restores ovulation in many cases | Potentially stronger metabolic effects (theoretical) |
| Availability | Widely available (brand + compounded) | Clinical trials only; compounded available from some suppliers |
| Cost (compounded) | $300-500/month | $300-500/month (variable) |
What the Glucagon Receptor Adds
Retatrutide's differentiator is the glucagon receptor. GLP-1 reduces appetite and slows gastric emptying. GIP enhances insulin secretion and supports fat metabolism. Glucagon — counterintuitively, since it raises blood sugar in acute settings — when chronically activated at lower levels increases energy expenditure, promotes liver fat reduction, and enhances lipid oxidation. The triple-agonist approach produces greater total weight loss than either single or dual agonists in early trial data.
A 2026 study in the International Journal of Obesity directly compared all three in animal models: Semaglutide produced 19.7% body weight reduction, Tirzepatide 31.6%, and Retatrutide 24.1% — with Tirzepatide actually outperforming Retatrutide in this particular model, though human Phase 2 data shows Retatrutide producing the highest human weight loss of any incretin therapy tested.
The Verdict
Choose Semaglutide if: You want the most-studied option with proven cardiovascular benefits, FDA approval, and the most established safety profile. For most women, this is still the appropriate first-line choice.
Consider Retatrutide if: You've plateaued on Semaglutide or Tirzepatide, you need more aggressive metabolic intervention, or liver fat (NAFLD/MAFLD) is a specific concern. Discuss with your provider — this is still investigational.
BioPure — Semaglutide BioPure — Retatrutide GLP-1 Research Lab